Analyst Ratings For Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP)
Today, SunTrust Banks lowered its price target on Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) to $12.00 per share.
There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) is Buy with a consensus target price of $16.00 per share, a potential 204.76% upside.
Some recent analyst ratings include
- 11/6/2018-Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) had its Buy rating reiterated by Cowen
- 9/17/2018-Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has coverage initiated with a Buy rating
- 3/17/2017-Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has coverage initiated with a Market Perform ➝ Market Perform rating
- On 10/1/2018 Gwendolyn Knowlt Binder-Scholl, Insider, sold 25,000 with an average share price of $13.79 per share and the total transaction amounting to $344,750.00.
- On 9/7/2018 Ali Behbahani, Director, bought 12,000,000 with an average share price of $1.67 per share and the total transaction amounting to $20,040,000.00.
- On 9/7/2018 Enterprise Associates 14 New, Major Shareholder, bought 3,000,000 with an average share price of $1.67 per share and the total transaction amounting to $5,010,000.00.
- On 8/29/2018 Gwendolyn Knowlt Binder-Scholl, Insider, sold 25,000 with an average share price of $10.25 per share and the total transaction amounting to $256,250.00.
- On 6/6/2018 Orbimed Advisors Llc, Director, sold 18,700 with an average share price of $13.56 per share and the total transaction amounting to $253,572.00.
- On 6/4/2018 Peter A Thompson, Director, sold 17,100 with an average share price of $13.57 per share and the total transaction amounting to $232,047.00.
- On 6/1/2018 Orbimed Advisors Llc, Director, sold 171,000 with an average share price of $13.51 per share and the total transaction amounting to $2,310,210.00.
About Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients. It is developing MAGE A-10 peptide that is in Phase I/II clinical trials for the treatment of urothelial, melanoma, and head and neck cancers, as well as non-small cell lung cancer (NSCLC); MAGE-A4 to treat urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, and gastric cancers; and AFP SPEAR T-cell therapeutic candidate that is in Phase I/II clinical trials for targeting a peptide associated with hepatocellular carcinoma. Adaptimmune Therapeutics plc has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO SPEAR T-cell program; and strategic alliance with The University of Texas MD Anderson Cancer Center for the development of T-cell therapies for various cancers. The company also has a clinical trial collaboration agreement with Merck & Co., Inc. for the assessment of NY-ESO SPEAR T-cell therapy in combination with anti-programmed death-1 inhibitor in patients with multiple myeloma; and a research, collaboration, and license agreement with Universal Cells, Inc. to gene editing and HLA-engineering technology, as well as a co-development and co-commercialization agreement with Bellicum Pharmaceutical Inc. to evaluate, develop, and commercialize next generation T-cell therapies. Adaptimmune Therapeutics plc was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Recent Trading Activity for Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP)
Shares of Adaptimmune Therapeutics PLC – ADR closed the previous trading session at 5,17 −0,080 1,52 % with shares trading hands.
